Compounds > isoleucine

isoleucine and Granulocytic Leukemia, Chronic

isoleucine has been researched along with Granulocytic Leukemia, Chronic in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's5 (62.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Digumarti, R; Gundeti, S; Kagita, S; Uppalapati, S1
Bertrand, A; Bonnet, ML; Brizard, F; Chomel, JC; Guilhot, F; Roy, L; Sorel, N; Turhan, AG1
Beug, H; Cerny-Reiterer, S; Gish, GD; Grebien, F; Hantschel, O; Kaupe, I; Koide, A; Koide, S; Kovacic, B; Pawson, T; Superti-Furga, G; Valent, P; Wojcik, J; Wyrzucki, AM1
Diwu, L; Dong, T; Huang, J; Huang, Q; Kuang, P; Liu, T; Lu, X; Meng, W; Wang, Y; Xiang, B; Yang, S; Ye, Y1
Ding, K; Leng, F; Li, Y; Long, H; Lu, X; Luo, J; Pan, X; Ren, X; Shen, M; Tu, Z; Wen, D; Zhang, F; Zhang, Z1
Fermeglia, M; Ferrone, M; Pricl, S; Tamborini, E1
Tuma, RS1
Apperley, JF; Davis, HP; de Lavallade, H; Goldman, JM; Kaeda, JS; Khorashad, JS; Marin, D; Milojkovic, D1

Other Studies

8 other study(ies) available for isoleucine and Granulocytic Leukemia, Chronic

ArticleYear
Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Threonine

2015
Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:11

    Topics: Aged; Amino Acid Substitution; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; Genes, abl; Humans; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation, Missense; Myeloid Progenitor Cells; Neoplastic Stem Cells; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Threonine

2010
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
    Cell, 2011, Oct-14, Volume: 147, Issue:2

    Topics: Amino Acid Sequence; Animals; Base Sequence; Benzamides; Cells, Cultured; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Molecular Sequence Data; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; src Homology Domains

2011
A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib.
    Leukemia research, 2012, Volume: 36, Issue:8

    Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Codon, Nonsense; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Models, Molecular; Phosphotransferases; Piperazines; Protein Structure, Tertiary; Pyrimidines

2012
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
    Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22

    Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Structure; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Threonine

2012
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:8

    Topics: Antineoplastic Agents; Benzamides; Computational Biology; Computer Simulation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Threonine

2005
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
    Journal of the National Cancer Institute, 2007, Feb-07, Volume: 99, Issue:3

    Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; Dasatinib; Drug Administration Schedule; Drug Costs; Fusion Proteins, bcr-abl; HIV Infections; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Threonine; United States

2007
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.
    Blood, 2007, Oct-01, Volume: 110, Issue:7

    Topics: Aged; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Interferon-alpha; Isoleucine; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Salvage Therapy; Tyrosine

2007